STOPCAP 2
Maximising patient benefit through enhanced evaluation of therapies and better characterisation of metastatic hormone-sensitive prostate cancer
Improving our understanding of metastatic prostate cancer and the effects of current and new treatments
What is this study about?
We want to find out which treatments for metastatic hormone-sensitive prostate cancer are the most effective, and for which men. We will do this by combining results and (anonymous) patient data from clinical trials to find out which characteristics of a man and his cancer are most useful for predicting his prognosis and his response to treatments.
We will also look for reliable early measures of whether a treatment is working, which can be used to shorten future trials, so men can access newer treatments sooner than they do now.
Finally, we will also try to ensure that the most effective treatments are used in clinical practice.
For more information, visit this Prostate Cancer UK project page.
Type of study
Meta-analyses
Contact details
Data Sharing
We will make STOPCAP data accessible (securely) for future research.
Who is funding the study?
The STOPCAP 2 collaboration is funded by Prostate Cancer UK.
When is it taking place?
This programme of research is ongoing.
Where is it taking place?
The programme is led by the MRC Clinical Trials Unit at University College London, and brings together the results of trials carried out worldwide
Who is included?
Trials that randomised men with metastatic hormone-sensitive prostate cancer.